Amerikanische Gesellschaft für Hirudotherapie

Linear Peptides Containing d-Leucine with Neuroprotective Activities from the LeechWhitman

Research article published in Journal of natural products (2019)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)ArzneimittelentwicklungZhang ZY et al. · Journal of natural products, 2019

Abstract

Three new linear peptides containing d-leucine, named whitmantides A-C (1-3), were isolated from the dried whole bodies of Whitmania pigra Whitman. Their structures with absolute configurations were elucidated by Edman degradation, mass spectrometry, Marfey's analysis, and solid-phase synthesis. It is the first time that peptides containing d-amino acid in leeches were discovered. Compounds 1-3 displayed neuroprotective activities against oxygen-glucose deprivation/reperfusion injury on Neuro-2a cells. In addition, ex vivo serum stability tests showed that 1-3 were resistant to protease degradation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsLeechesLeucineNeuroprotective AgentsPeptides

Zusammenfassung

Three new linear peptides containing d-leucine, named whitmantides A-C (-), were isolated from the dried whole bodies ofWhitman.

Warum dies für die Hirudotherapie relevant ist

This study isolated three new linear peptides containing d-leucine, named whitmantides A–C, from dried whole bodies of the leech Whitmania pigra, marking the first reported discovery of d-amino-acid-containing peptides in leeches. Structures were determined by Edman degradation, mass spectrometry, Marfey's analysis, and solid-phase synthesis. The compounds showed neuroprotective activity against oxygen-glucose deprivation/reperfusion injury in Neuro-2a cells and resisted protease degradation in ex vivo serum stability tests. For ASH's domain, this is a directly relevant characterization of novel bioactive peptides from a leech source with potential neuroprotective application. The caveat is that findings are preclinical and limited to cell-based and serum-stability assays, with no in-vivo or clinical evidence.

Zitation

Linear Peptides Containing d-Leucine with Neuroprotective Activities from the LeechWhitman

Zhang ZY et al. · Journal of natural products, 2019

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.